ABOUT US About Celltrion Notice Media Center BUSINESS Business Areas R&D Production Distribution PRODUCTS Products Pipeline ESG Environmental Social Governance ESG Archive IR Financial Information Stock Summary Public Disclosures IR Archive CAREERS Our Values How to Apply Jobs KOR ENG Choose Other Countries Europe Asia Pacific North America Latin America close Denmark Finland (FI) Finland (SV) France Germany Hungary Ireland Italy Netherlands Norway (NO) Norway (SV) Sweden Swiss Turkey United Kingdom Korea (HQ) Korea (EN) Japan Australia Canada (EN) Canada (FR) USA Brazil Colombia Chile Peru Mexico
Category IR Approvals General Other All Title Content delete search IR [Letter to Shareholders – Notice Regarding Bonus Issue of Shares] 2025.05.26 Top-pinned content General Letter to Shareholders [Explanation and Company Position Regarding the U.S. Government's Follow-Up Measures on the Drug Price Reduction Executive Order Issued by the Trump Administration] 2025.05.21 Top-pinned content General [Letter to Our Shareholders] Notice of an Upcoming Shareholder Meeting and Initiatives to Enhance Shareholder Value 2025.05.18 Top-pinned content IR [Letter to Shareholders – Notice Regarding Bonus Issue of Shares] 2025.05.26 General Letter to Shareholders [Explanation and Company Position Regarding the U.S. Government's Follow-Up Measures on the Drug Price Reduction Executive Order Issued by the Trump Administration] 2025.05.21 General [Letter to Our Shareholders] Notice of an Upcoming Shareholder Meeting and Initiatives to Enhance Shareholder Value 2025.05.18 General [Notice] Celltrion Online Conference Video Now Available 2025.05.15 General [Letter to Our Esteemed Shareholders] Company Response Strategy Regarding the Trump Administration's Executive Order on Most-Favored-Nation Drug Pricing 2025.05.13 General Notice to Shareholders [UPDATE – Company’s Position and Response Strategy Regarding the U.S. Trump Administration’s Tariff Policy(3)] 2025.05.07 Other Notice to Shareholders [Guideline for Implementing the Shareholder Return Plan that Prioritizes Enhancing Shareholder Value] 2025.04.02 General Notice to Shareholders [UPDATE - Company's Position and Response Strategy Regarding the U.S. Trump Administration's Tariff Policy(2)] 2025.02.19 General Notice to Shareholders [Response Strategy to the U.S. Trump Administration’s Tariff Policy on Pharmaceuticals] 2025.01.30 General Notice to Shareholders Regarding Updates on Our Business Progress 2024.12.04 First 1 2 3 4 Last